Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 13/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | MITF | O75030 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | APAF1 | O14727 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PTPRC | P08575 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18731151 | 0.91 | STAT3 (0.53) | STAT3ALDH1A1MAPTMITFLMNA | |
| SCHEMBL18691819 | 0.89 | STAT3 (0.52) | STAT3ALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL17345513 | 0.89 | STAT3 (0.59) | STAT3ALDH1A1MAPTMITFLMNA | |
| SCHEMBL18730814 | 0.89 | STAT3 (0.52) | STAT3ALDH1A1MAPTMITFLMNA | |
| SCHEMBL17345553 | 0.88 | STAT3 (0.60) | STAT3ALDH1A1MAPTMITFLMNA | |
| SCHEMBL18807113 | 0.88 | STAT3 (0.57) | STAT3ALDH1A1MAPTMITFLMNA | |
| SCHEMBL17345498 | 0.87 | STAT3 (0.56) | STAT3ALDH1A1MAPTMITFLMNA | |
| SCHEMBL18730823 | 0.87 | STAT3 (0.56) | STAT3ALDH1A1MAPTMITFLMNA | |
| SCHEMBL18731231 | 0.87 | STAT3 (0.52) | STAT3ALDH1A1MAPTMITFLMNA | |
| SCHEMBL17345568 | 0.87 | STAT3 (0.55) | STAT3ALDH1A1MAPTMITFLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005752-B2 | Anticancer agent | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2018-06-26 | — | — | US | disclosed |
| US-20170121299-A1 | NOVEL ANTICANCER AGENT | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121299-A1 | NOVEL ANTICANCER AGENT | NTPCR, TP53, NME1 | STAT3 1231/4885ALDH1A1 187/4885MAPT 4391/4885 |
| US-10005752-B2 | Anticancer agent | TP53, NTPCR, NQO1 | STAT3 1303/4885ALDH1A1 160/4885MAPT 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.